Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | -15.0% | -- | -- | -- | -800.0% | Decelerating |
| Sales | +15.0% | +2.0% | +1.0% | -- | +14.0% | Stable |
| Return | -- | -- | -- | -- | -- | -- |
| ROE | +10.0% | +2.0% | -4.0% | -- | -- | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 6 | 5 | 7 | 4 | 7 | 4 | 5 | 3 | 4 | 3 | 4 | 4 | 5 |
| Expenses | 4 | 4 | 5 | 7 | 4 | 6 | 4 | 5 | 3 | 4 | 3 | 3 | 4 | 4 |
| Operating Profit | 0 | 1 | -0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | -0 | 1 | -0 | 1 |
| OPM % | 0.9% | 19.1% | -1.2% | 2.8% | 4.5% | 12.1% | 5.9% | 17.6% | 6.7% | 7.9% | -2.8% | 31.4% | -2.0% | 19.8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -1 | 1 | -1 | -0 | -0 | 0 | -0 | 0 | -0 | -0 | -1 | 1 | -1 | 0 |
| Tax % | 0.0% | -11.1% | 0.0% | 0.0% | 0.0% | 34.5% | 0.0% | 0.0% | 0.0% | -23.1% | 0.0% | 0.0% | 0.0% | 44.7% |
| Net Profit | -1 | 1 | -1 | -0 | -0 | 0 | -0 | 0 | -0 | -0 | -1 | 1 | -1 | 0 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | -1.9 | 1.9 | -2.3 | -1.4 | -1.5 | 0.6 | -1.5 | 1.4 | -0.8 | -0.7 | -1.7 | 2.8 | -1.7 | 0.8 |
| Sales Growth (YoY) | -- | -17.7% | 31.2% | 25.6% | 39.3% | 50.1% | 20.5% | 25.2% | -35.1% | -8.3% | -54.8% | -1.4% | -3.3% | -- |
| Sales Growth (QoQ) | -- | 8.1% | -25.9% | 73.0% | -40.6% | 72.2% | -29.1% | 91.9% | -36.0% | 38.2% | -26.3% | -0.5% | -9.5% | -- |
| OP Growth (YoY) | -77.8% | 29.6% | -126.1% | -80.2% | -5.3% | 131.4% | 355.6% | -29.9% | 311.1% | -63.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | -96.2% | 1850.0% | -131.6% | 5.6% | -77.8% | 252.2% | -76.0% | 405.3% | -45.7% | 488.9% | -106.6% | 1622.2% | -109.4% | -- |
| Profit Growth (YoY) | -26.1% | 215.8% | -48.9% | -204.8% | -91.7% | 195.0% | 9.6% | -50.6% | 52.9% | -176.9% | -161.9% | 1316.7% | 16.4% | -- |
| EPS Growth (YoY) | -- | 214.5% | -49.0% | -204.4% | -92.3% | 195.4% | 9.5% | -50.5% | 53.0% | -176.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 185.5% | -59.4% | 4.7% | -341.9% | 140.5% | -211.7% | 275.6% | -20.0% | 61.5% | -161.0% | 266.9% | -295.3% | -- |
| OP Margin | -- | 19.1% | -1.2% | 2.8% | 4.5% | 12.1% | 5.9% | 17.6% | 6.7% | 7.9% | -2.8% | 31.4% | -2.0% | 19.8% |
| Net Margin | -- | 10.9% | -13.8% | -6.4% | -11.6% | 2.8% | -12.1% | 7.7% | -8.4% | -4.5% | -16.1% | 19.4% | -11.6% | 5.4% |
| Material Cost % | -- | 16.4% | 30.4% | 35.7% | 10.3% | 32.3% | 20.9% | 18.3% | 11.2% | 15.1% | 36.3% | -9.4% | 37.6% | 0.4% |
| Employee Cost % | -- | 13.4% | 17.1% | 10.8% | 19.4% | 12.3% | 22.9% | 15.9% | 28.1% | 22.5% | 26.4% | 14.4% | 20.1% | 21.9% |
| P/S | 1.15 | 1.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.48 | 2.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50please find enclosed herewith the Newspaper advertisement of unaudited financial result for the quarter ended 30th June 2026
with reference to the outcome of board meeting held on 12th August 2026. we hereby submit corrigendum to rectify a typographical error in book closure date and benpose date
Submission of standalone Unaudited Financial Results for the first quarter ended on 30.06.2026
Submission of standalone Unaudited Financial Results for the first quarter ended on 30.06.2026
as per attachment
Chemiesynth (Vapi) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Standalone Unaudited Financial ....
Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018
Closure of trading window for considering un-audited financial results for the quarter ending June 30, 2026
Newspaper Publication with respect to Audited standalone financial statement for quarter and year ended March 31, 2026
Audited Financial Results along with Auditor''s Report for the Quarter & Year ended 31.03.2026
outcome of the meeting of the Board of director held on held on 27th May 2026
Chemiesynth (Vapi) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
The compliance letter of statement of deviation under Regulation 32(1) of SEBI LODR is filed for taking on record.
Please find attached declaration about non applicability of Regulation 24(A) for year ended March 31, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended March 31, 2026
Appointment of Internal Auditor for the Financial Year 2025-26 & 2026-27.
Disclosure under regulation 30 of SEBI (LODR) Regulation, 2015 -appointment of Internal Auditor for the financial year 2025-26 & 2026-27
Pursuant to SEBI(PIT) Regulation, 2015 the trading window for dealing in the equity shares of the company will be closed for all directors, designated persons, connected person and immediate ....
please find enclosed herewith the newspaper Advertisement Published on 14th February 2026 regarding the un-audited financial results for the quarter and nine months ended 31st December, 2025
Approval Of Unaudited Standalone Financial Result of the Company for the Quarter Ended On 31St December 2025
Unaudited standalone Financial Result for the quarter ended December 31, 2025
as per annexure
Chemiesynth (Vapi) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve Standalone Unaudited Financial ....
Report on Re-lodgment of transfer requests of Physical share
Enclosed confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended 31st December 2025
Pursuant to the SEBI (PIT) Regulation, 2015 the trading window for dealing in the equity shares of the company will be closed for all Directors, Designated Persons, Connected Persons and ....
Pursuant to Regulation 30 of the SEBI (LODR) Regulation 2015, the Board of Directors in the meeting held on 5th December 2025 approved the appointment of Mr. Suresh Lad as a Chief Financial ....
Report on Re- Lodgement of transfer requests of Physical shares
Intimation of Newspaper Publication
Chemiesynth (Vapi) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Un-Audited Financial Results ....
certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2025
Scrutinizer Report along with voting results on the resolution passed at the 39th Annual General meeting of the company held on 30th September 2025
We regret to inform you that the sad demise of Mr. Parimal A Desai, Chief Financial Officer of the company.
Attached the Letter of weblink sent to the shareholder
Newspaper Publication for 39th Annual General Meeting
Notice of the 39th Annual General meeting to be held on 30th September 2025 at 11:00 am at the Registered office of the company
Annual Report for the financial year 2024-2025
Financial result for the quarter ended 30th June, 2025
Book closure date
The Board of Directors of the Company at its meeting held today, i.e. August 12, 2025, have inter-alia, considered and approved Standalone Un-Audited Financial Results for quarter ended ....
Pursuant to regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018. we are enclosing the certificate issue by Purva sharegistry (India ) Pvt ltd, RTA for the quarter ....
Closure of Trading window for the quarter ended June 30, 2025
Publication of the financial Result for the quarter and year ended March, 31, 2025
Integrated filing for the quarter and year ended March 31, 2025
submission of Audited standalone Financial Results for the Quarter and financial year ended March, 31 2025
The Board of Directors approved Audited Standalone Financial Results for the quarter & year ended 31.03.2025
Chemiesynth (Vapi) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 ,inter alia, to consider and approve Chemiesynth (Vapi) Ltd has ....
Chemiesynth (Vapi) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 ,inter alia, to consider and approve Audited standalone financial ....
please find attached declaration about non applicability of Regulation 24(A) for year ended March 31, 2025